Research programme: PPAR agonists - Genfit

Drug Profile

Research programme: PPAR agonists - Genfit

Alternative Names: Compound 18; G 200; G120; G150; G170; GFT120

Latest Information Update: 03 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genfit
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Atherosclerosis; Diabetes mellitus; Dyslipidaemias; Hypertension; Obesity

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics data from preclinical trials in Dyslipidaemias presented at the 240th American Chemical Society National Meeting (ACS-2010)
  • 12 Feb 2008 Preclinical development is ongoing
  • 12 Feb 2008 Preclinical trials in Atherosclerosis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top